[go: up one dir, main page]

AR041835A1 - Compuestos de purina y usos de los mismos - Google Patents

Compuestos de purina y usos de los mismos

Info

Publication number
AR041835A1
AR041835A1 ARP030103918A ARP030103918A AR041835A1 AR 041835 A1 AR041835 A1 AR 041835A1 AR P030103918 A ARP030103918 A AR P030103918A AR P030103918 A ARP030103918 A AR P030103918A AR 041835 A1 AR041835 A1 AR 041835A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
members
fully saturated
partially
Prior art date
Application number
ARP030103918A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR041835A1 publication Critical patent/AR041835A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)

Abstract

Se describen en la presente compuestos que actรบan como ligandos de receptor de cannabinoides y sus usos en el tratamiento de enfermedades ligadas a la mediaciรณn de los receptores de cannabinoide en animales. Reivindicaciรณn 1: Un compuesto de fรณrmula (1), caracterizado porque: A es un arilo opcionalmente sustituido o un heteroarilo opcionalmente sustituido; B es un arilo sustituido o un heteroarilo opcionalmente sustituido; R1 es hidrรณgeno, alquilo (C1-4), alquilo (C1-4) sustituido con halo o alcoxi (C1-4); R4 es: (i) un restos de grupo de fรณrmula (2), en las que R4a es hidrรณgeno o alquilo (C1-3); cada R4b y R4b' es independientemente hidrรณgeno, ciano, hidroxi, amino, H2NC(O)-, o un resto quรญmico seleccionado del grupo constituido por alquilo (C1-6), alcoxi (C1-6), aciloxi, acilo, alquil(C1-3)-O-C(O)-, alquil(C1-4)-NH-C(O)-, (alquil (C1-4))2N-C(O)-, alquil(C-16)amino-, (alquil (C1-4))2amino-, cicloalquil(C3-6)aminoi-, acilamino, arilalquil(C1-4)amino-, heteroarilalquil(C1-4)amino-, arilo, heteroarilo, un heterociclo parcial o totalmente saturado de 3 a 6 miembros y un anillo carbocรญclico parcial o totalmente saturado de 3 a 8 miembros, estando el resto opcionalmente sustittuido; o R4b o R4b' tomado conjuntamente con R4e, R4e', R4f o R4f' forma un enlace, un puente metileno o un puente etileno; X es un enlace, -CH2-CH2- o -C(R4c)(R4c')-, siendo cada R4c y R4c' independientemente hidrรณgeno, ciano, hidroxi, amino, H2NC(O)- o un resto quรญmico seleccionado del grupo constituido por alquilo (C1-6), alcoxi (C1-6), aciloxi, acilo, alquil(C1-3)-O-C(O)-, alquil(C1-4)-NH-C(O)-, (alquil (C1-4))2N-C(O)-, alquil(C1-6)amino-, dialquil(C1-4)amino-, cicloalquil(C3-6)amino-, arilalquil(C1-4)amino-, heteroarilalquil(C1-4)amino-, arilo, heteroarilo, un heterociclo parcial o totalmente saturado de 3 a 6 miembros y un anillo carbocรญclico parcial o totalmente saturado de 3 a 8 miembros, estando opcionalmente sustituido el resto; o R4c y R4c' tomado conjuntamente con R4e, R4e', R4f o R4f' forma un enlace, un puente metileno o un puente etileno; Y es oxรญgeno, azufre, -C(O)-, -C(=N-OH)- o -C(R4d)(R4d')-, siendo cada R4d y R4d' independientemente hidrรณgeno, ciano, hidroxi, amino, H2NC(O)-, o un resto quรญmico seleccionado del grupo constituido por alquilo (C1-6), alcoxi (C1-6), aciloxi, acilo, alquil(C1-3)-O-C(O)-, alquil(C1-4)-NH-C(O)-, (alquil (C1-4))2N-C(O)-, HO-NH-, alquil(C1-6)-amino-, dialquil(C1-4)amino-, cicloalquil(C3-6)amino-, acilamino-, arilalquil(C1-4)amino-, heteroarilalquil(C1-4)amino-, arilo, heteroarilo, un heterociclo parcial o totalmente saturado de 3 a 6 miembros y un anillo carbocรญclico parcial o totalmente saturado de 3 a 8 miembros, estando el citado resto opcionalmente sustituido; o R4d y R4d' tomados conjuntamente forman un anillo heterocรญclico parcial o totalmente saturado de 3 a 6 miembros, un anillo lactona de 5 รณ 6 miembros o un anillo lactama de 4 a 6 miembros, estando opcionalmente sustituidos el citado anillo heterocรญclico, el citado anillo lactona y el citado anillo lactama y conteniendo opcionalmente el citado anillo lactona y el citado anillo lactama un heteroรกtomo adicional seleccionado del oxรญgeno, nitrรณgeno o azufre; o Y es -NR4d''-, siendo R4d'' un hidrรณgeno o un resto quรญmico seleccionado del grupo constituido por alquilo (C1-6), cicloalquilo (C3-6), alquil(C1-3)sulfonil-, alquil(C1-3)aminosulfonil-, dialquil(C1-3)aminosulfonil-, acilo, alquil(C1-6)-O-C(O)-, arilo y heteroarilo, estando opcionalmente sustituido el citado resto; Z es un enlace, -CH2CH2- o -C(R4e)(R4e')-, siendo cada R4e y R4e' independientemente hidrรณgeno, ciano, hidroxi, amino, H2NC(O)- o un resto quรญmico seleccionado del grupo constituido por alquilo (C1-6), alcoxi (C1-6), aciloxi, acilo, alquil(C-3)-O-C(O)-, alquil(C1-4)-NH-C(O)-, (alquil (C1-4))2N-C(O)-, alquil(C1-6)amino-, dialquil(C1-4)amino-, cicloalquil(C3-6)amino-, acilamino-, arilalquil(C1-4)amino-, heteroarilalquil(C1-4)amino-, arilo, heteroarilo, un heterociclo parcial o totalmente saturado de 3 a 6 miembros y un anillo carbocรญclico parcial o totalmente saturado de 3 a 8 miembros, estando opcionalmente sustituido el citado resto; o R4e o R4e' tomado conjuntamente con R4b, R4b', R4c o R4c' forma un enlace, un puente metileno o un puente etileno; y cada R4f y R4f' es independientemente hidrรณgeno, ciano, hidroxi, amino, H2NC(O)- o un resto quรญmico seleccionado del grupo constituido por alquilo (C1-6), alcoxi (C1-6), aciloxi, acilo, alquil(C1-3)-O-C(O)-, alquil(C1-4)-NH-C(O)-, (alquil (C1-4))2N-C(O)-, alquil(C1-6)amino-, dialquil(C1-4)amino-, cicloalquil(C3-6)amino-, acilamino-, arilalquil(C1-4)amino-, heteroarilalquil(C1-4)amino-, arilo, heteroarilo, un heterociclo parcial o totalmente saturado de 3 a 6 miembros y un anillo carbocรญclico parcial o totalmente saturado de 3 a 8 miembros, estando opcionalmente sustituido el citado resto; o R4f o R4f' tomado conjuntamente con R4b, R4b', R4c 0 R4c' forma un enlace, un puente metileno o un puente etileno; con la condiciรณn de que cuando R4 es un grupo de fรณrmula (2), entonces a) al menos uno de R4b, R4b', R4c, R4c', R4d, R4d', R4d'', R4e, R4e', R4f y R4f' sea distinto de hidrรณgeno, alquilo (C1-4) o alquilo (C1-4) sustituido con halo; y b) Y no sea oxรญgeno, azufre ni -NH- cuando X y Z son un enlace, -CH2- o -CH2CH2-, y R4b, R4b', R4f y R4f' son hidrรณgeno; o (ii) un grupo que tiene la fรณrmula (4), en la que cada R5 y R6 es independientemente hidrรณgeno o alquilo (C1-4), y R7 es alquil (C1-4)-, alquil (C1-4)- sustituido con halo, alcoxi(C1-4)alquil(C1-4)-, alquil(C1-4)aminoalquil(C1-4)-, dialquil(C1-4)aminoalquil(C1-4)- o un anillo heterocรญclico parcial o totalmente saturado de 4 a 6 miembros que contiene de 1 a 2 heteroรกtomos independientemente seleccionados de oxรญgeno, azufre o nitrรณgeno; o R5 y R6 o R5 y R7 tomados conjuntamente forman un lactona de 5 รณ 6 miembros, una lactama de 4 a 6 miembros o un heterociclo parcial o totalmente saturado de 4 a 6 miembros que contiene de 1 a 2 heteroรกtomos independientemente seleccionados de oxรญgeno, azufre o nitrรณgeno, estando opcionalmente sustituidos la citada lactona, la citada lactama y el citado heterociclo; una sal farmacรฉuticamente aceptable del mismo, un profรกrmaco del citado compuesto o la citada sal, o un solvato o hidrato del citado compuesto, la citada sal o el citado profรกrmaco.
ARP030103918A 2002-10-28 2003-10-27 Compuestos de purina y usos de los mismos AR041835A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42187402P 2002-10-28 2002-10-28

Publications (1)

Publication Number Publication Date
AR041835A1 true AR041835A1 (es) 2005-06-01

Family

ID=32176739

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103918A AR041835A1 (es) 2002-10-28 2003-10-27 Compuestos de purina y usos de los mismos

Country Status (44)

Country Link
US (2) US7129239B2 (es)
EP (1) EP1558615B8 (es)
JP (2) JP3954618B2 (es)
KR (1) KR100674560B1 (es)
CN (3) CN100478343C (es)
AP (1) AP1916A (es)
AR (1) AR041835A1 (es)
AT (1) ATE371658T1 (es)
AU (1) AU2003269368B2 (es)
BR (1) BR0314918A (es)
CA (1) CA2503900C (es)
CO (1) CO5560546A2 (es)
CR (1) CR7812A (es)
CU (1) CU23535A3 (es)
CY (1) CY1107505T1 (es)
DE (1) DE60316012T2 (es)
DK (1) DK1558615T3 (es)
DO (1) DOP2003000742A (es)
EA (1) EA008176B1 (es)
EC (1) ECSP055767A (es)
EG (1) EG24662A (es)
ES (1) ES2291669T3 (es)
GE (1) GEP20084325B (es)
GT (1) GT200300232A (es)
HR (1) HRP20050378A2 (es)
IS (1) IS2602B (es)
MA (1) MA27479A1 (es)
MX (1) MXPA05003882A (es)
MY (1) MY140010A (es)
NL (1) NL1024643C2 (es)
NO (1) NO332195B1 (es)
NZ (1) NZ539589A (es)
OA (1) OA13080A (es)
PE (1) PE20040781A1 (es)
PL (1) PL376311A1 (es)
PT (1) PT1558615E (es)
RS (2) RS20050306A (es)
SG (1) SG148071A1 (es)
TN (1) TNSN05121A1 (es)
TW (1) TWI327567B (es)
UA (1) UA79507C2 (es)
UY (1) UY28044A1 (es)
WO (1) WO2004037823A1 (es)
ZA (1) ZA200503378B (es)

Families Citing this family (85)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
ES2323357T3 (es) * 1999-11-12 2009-07-14 Biogen Idec Ma Inc. Policicloalquilpurinas como antagonistas del receptor de adenosina.
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
US7241890B2 (en) * 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
EP1546115A4 (en) 2002-09-27 2010-08-04 Merck Sharp & Dohme Substituted pyrimidines
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
CN102558155A (zh) * 2003-01-14 2012-07-11 ้˜ฟไผฆ็บณ่ฏๅ“ๅ…ฌๅธ ไฝœไธบไปฃ่ฐข่ฐƒ่Š‚ๅ‰‚็š„่ŠณๅŸบๅ’Œๆ‚่ŠณๅŸบ่ก็”Ÿ็‰ฉๅŠๅ…ถๆ‰€ๆถ‰ๅŠ็š„็–พ็—…ๅฆ‚็ณ–ๅฐฟ็—…ๅ’Œ้ซ˜่ก€็ณ–็—‡็š„้ข„้˜ฒๅ’Œๆฒป็–—
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
EP1603585A2 (en) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
CA2524397A1 (en) * 2003-05-07 2004-11-18 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US7232823B2 (en) * 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
AU2004257267B2 (en) 2003-07-14 2009-12-03 Arena Pharmaceuticals,Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20050026983A1 (en) * 2003-07-30 2005-02-03 Pfizer Inc Imidazole compounds and uses thereof
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
JP2008517898A (ja) * 2004-10-22 2008-05-29 ใƒ•ใ‚กใ‚คใ‚ถใƒผใƒปใƒ—ใƒญใƒ€ใ‚ฏใƒ„ใƒปใ‚คใƒณใ‚ฏ ใƒ—ใƒชใƒณๅŒ–ๅˆ็‰ฉใ‚’่ชฟ่ฃฝใ™ใ‚‹ใŸใ‚ใฎๆ–นๆณ•
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
AR051596A1 (es) * 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
KR20070089151A (ko) * 2004-11-16 2007-08-30 ์ง€๋”๋ธ”์œ  ํŒŒ๋งˆ ๋ฆฌ๋ฏธํ‹ฐ๋“œ ์นด๋‚˜๋น„๋…ธ์ด๋“œ์˜ ์ƒˆ๋กœ์šด ์šฉ๋„
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
CA2605479A1 (en) * 2005-04-20 2006-10-26 Pfizer Products Inc. Acylaminobicyclic heteroaromatic compounds and uses thereof
CA2609783A1 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
BRPI0613505A2 (pt) 2005-06-30 2011-01-11 Prosidion Ltd agonistas de gpcr
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7601713B2 (en) 2005-12-15 2009-10-13 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
EP1962863A4 (en) * 2005-12-22 2010-11-24 Conforma Therapeutics Corp ORALLY ACTIVE PURINE INHIBITORS OF THERMAL SHOCK PROTEIN 90
US20090264470A1 (en) * 2006-02-21 2009-10-22 Bennett Teresa A CB1 Antagonists and Inverse Agonists
SG185849A1 (en) 2006-02-23 2012-12-28 Pfizer Ltd Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
WO2008044111A1 (en) * 2006-10-13 2008-04-17 Pfizer Products Inc. Pharmaceutical formulation tablet
JP2010509392A (ja) 2006-11-13 2010-03-25 ใƒ•ใ‚กใ‚คใ‚ถใƒผใƒปใƒ—ใƒญใƒ€ใ‚ฏใƒ„ใƒปใ‚คใƒณใ‚ฏ ใ‚ธใ‚ขใƒชใƒผใƒซใ€ใ‚ธใƒ”ใƒชใ‚ธใƒ‹ใƒซใŠใ‚ˆใณใ‚ขใƒชใƒผใƒซโˆ’ใƒ”ใƒชใ‚ธใƒ‹ใƒซ่ช˜ๅฐŽไฝ“ใชใ‚‰ใณใซใใฎไฝฟ็”จ
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
AR064735A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
WO2008081208A1 (en) 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
US20100048632A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine GPCR Agonists
CL2008000017A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
US20080220104A1 (en) * 2007-03-08 2008-09-11 Cappello John V Compositions for producing satiety
KR101643237B1 (ko) 2007-10-05 2016-07-27 ๋ฒ ๋ผ์Šคํ…œ, ์ธ์ฝ”ํฌ๋ ˆ์ดํ‹ฐ๋“œ ํ”ผ๋ฆฌ๋ฏธ๋”˜ ์น˜ํ™˜๋œ ํ“จ๋ฆฐ ์œ ๋„์ฒด
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
RU2010125121A (ru) * 2007-11-21 2011-12-27 ะญะฑะฑะพั‚ ะ›ัะฑะพั€ะตั‚ั€ะธะท (Us) ะ‘ะธะฐั€ะธะปะทะฐะผะตั‰ะตะฝะฝั‹ะต ะฟั€ะพะธะทะฒะพะดะฝั‹ะต ะฐะทะฐะฑะธั†ะธะบะปะธั‡ะตัะบะธั… ะฐะปะบะฐะฝะพะฒ
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
DK2326638T5 (da) 2008-08-06 2014-01-13 Pfizer Ltd Diazepin- og diazocan-forbindelser som mc4-agonister
WO2010019762A1 (en) * 2008-08-13 2010-02-18 Jenrin Discovery Purine compounds as cannabinoid receptor blockers
PE20110828A1 (es) 2008-10-31 2011-11-22 Genentech Inc Compuestos de pirazolopirimidina como inhibidores de jak
UA104010C2 (en) * 2008-12-18 2013-12-25 ะญะปะธ ะ›ะธะปะปะธ ะญะฝะด ะšะพะผะฟะฐะฝะธ Purine compounds
EP2246335A1 (de) * 2009-02-17 2010-11-03 Bayer CropScience AG Aminopyrimidinamide als Schรคdlingsbekรคmpfungsmittel
ES2500643T3 (es) 2009-04-03 2014-09-30 Verastem, Inc. Compuestos de purina sustituidos con pirimidina como inhibidores de las cinasas
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
KR101414012B1 (ko) 2009-11-13 2014-07-01 ์ฃผ์‹ํšŒ์‚ฌ ๋…น์‹ญ์ž ์•„๋ฆดํ”ผํŽ˜๋ผ์ง„-ํ•จ์œ  ํ“จ๋ฆฐ ์œ ๋„์ฒด ๋ฐ ๊ทธ์˜ ์šฉ๋„
RU2012141536A (ru) * 2010-03-17 2014-04-27 ะค. ะฅะพั„ั„ะผะฐะฝะฝ-ะ›ั ะ ะพัˆ ะะณ ะ˜ะผะธะดะฐะทะพะฟะธั€ะธะดะธะฝั‹, ะบะพะผะฟะพะทะธั†ะธะธ ะธ ัะฟะพัะพะฑั‹ ะฟั€ะธะผะตะฝะตะฝะธั
ES2481867T3 (es) * 2010-03-31 2014-07-31 Eli Lilly And Company Compuestos de purina usados como agonistas de CB2
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor
JP2013528598A (ja) 2010-05-11 2013-07-11 ใƒ•ใ‚กใ‚คใ‚ถใƒผใƒปใ‚คใƒณใ‚ฏ ใƒŸใƒใƒฉใƒซใ‚ณใƒซใƒใ‚ณใ‚คใƒ‰ๅ—ๅฎนไฝ“ๆ‹ฎๆŠ—่–ฌใจใ—ใฆใฎใƒขใƒซใƒ›ใƒชใƒณๅŒ–ๅˆ็‰ฉ
BR112013006016A2 (pt) 2010-09-15 2016-06-07 Hoffmann La Roche compostos de azabenzotiazol, composiรงรตes e mรฉtodos de uso
EA201390421A1 (ru) 2010-09-22 2013-09-30 ะั€ะตะฝะฐ ะคะฐั€ะผะฐััŒัŽั‚ะธะบะฐะปะท, ะ˜ะฝะบ. ะœะพะดัƒะปัั‚ะพั€ั‹ ั€ะตั†ะตะฟั‚ะพั€ะฐ gpr119 ะธ ะปะตั‡ะตะฝะธะต ัะฒัะทะฐะฝะฝั‹ั… ั ะฝะธะผ ะฝะฐั€ัƒัˆะตะฝะธะน
BR112013011520A2 (pt) 2010-11-19 2019-09-24 Hoffmann La Roche pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
WO2013041539A1 (en) * 2011-09-20 2013-03-28 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
CZ305750B6 (cs) * 2012-01-26 2016-03-02 รšstav Organickรฉ Chemie A Biochemie Akademie Vฤ›d ฤŒr, V.V.I. Zpลฏsob vรฝroby N-9 substituovanรฝch analogลฏ purinu
JP6215237B2 (ja) * 2012-02-17 2017-10-18 ใƒชใ‚ตใƒผใƒใƒปใƒˆใƒฉใ‚คใ‚ขใƒณใ‚ฐใƒซใƒปใ‚คใƒณใ‚นใƒ†ใ‚ฃใƒใƒฅใƒผใƒˆ ๆœซๆขข้™ๅฎš็š„ใ‚ธใƒ•ใ‚งใƒ‹ใƒซใƒ—ใƒชใƒณ่ช˜ๅฐŽไฝ“
RU2485939C1 (ru) * 2012-06-19 2013-06-27 ะกั‚ะฐะฝะธัะปะฐะฒ ะะฝะฐั‚ะพะปัŒะตะฒะธั‡ ะšะตะดะธะบ ะžั„ั‚ะฐะปัŒะผะพะปะพะณะธั‡ะตัะบะธะน ะฟั€ะตะฟะฐั€ะฐั‚ ะฒ ะฒะธะดะต ะณะปะฐะทะฝั‹ั… ะบะฐะฟะตะปัŒ, ัะพะดะตั€ะถะฐั‰ะธะน ะดะธััƒะปัŒั„ะธั€ะฐะผ ะธ ั‚ะฐัƒั€ะธะฝ
HRP20181141T1 (hr) * 2013-05-02 2018-09-21 F. Hoffmann - La Roche Ag Derivati purina kao agonisti cb2 receptora
AU2015217802B2 (en) 2014-02-17 2019-06-06 Bayer Cropscience Aktiengesellschaft 2-(het)aryl-substituted condensed bicyclic heterocycle derivatives as pest control agents
AU2015261812B2 (en) 2014-05-23 2019-11-21 F. Hoffmann-La Roche Ag 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
CN104581617A (zh) * 2015-01-22 2015-04-29 ๅฐ็ฑณ็ง‘ๆŠ€ๆœ‰้™่ดฃไปปๅ…ฌๅธ ๆ— ็บฟ้€šไฟกๆ–นๆณ•ๅ’Œๆ™บ่ƒฝ่ฎพๅค‡
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sรณl L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach zwiฤ…zanych z receptorem S1P1
WO2018119076A1 (en) 2016-12-21 2018-06-28 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
CN110520124A (zh) 2017-02-16 2019-11-29 ่‰พๅฐผ็บณๅˆถ่ฏๅ…ฌๅธ ็”จไบŽๆฒป็–—ๅŽŸๅ‘ๆ€ง่ƒ†ๆฑๆ€ง่ƒ†็ฎก็‚Ž็š„ๅŒ–ๅˆ็‰ฉๅ’Œๆ–นๆณ•
JP7256757B2 (ja) 2017-05-22 2023-04-12 ใ‚จใƒ•๏ผŽ ใƒ›ใƒ•ใƒžใƒณ๏ผใƒฉ ใƒญใ‚ทใƒฅ ใ‚ขใƒผใ‚ฒใƒผ ๅ‡ฆ็ฝฎ็”จๅŒ–ๅˆ็‰ฉๅŠใณ็ต„ๆˆ็‰ฉใ€ไธฆใณใซใใฎไฝฟ็”จๆ–นๆณ•
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN113454059B (zh) * 2019-01-15 2025-05-27 ่€ถ่ทฏๆ’’ๅ†ทๅธŒไผฏๆฅๅคงๅญฆไผŠๆฃฎๅง†็ ”็ฉถๅ‘ๅฑ•ๆœ‰้™ๅ…ฌๅธ ๅ…ทๆœ‰ๆ— ็Žฏไธป้“พ็š„cb1rๅ—ไฝ“้˜ปๆ–ญๅ‰‚
PH12022550188A1 (en) 2019-07-24 2022-11-21 Constellation Pharmaceuticals Inc Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide

Family Cites Families (76)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
US3018378A (en) * 1954-09-20 1962-01-23 North American Aviation Inc Radiant energy scanning system
US3016378A (en) * 1959-07-01 1962-01-09 Thomae Gmbh Dr K Amino-substituted purine derivatives
GB1165283A (en) 1967-01-17 1969-09-24 Science Union & Cie New Purine Derivatives and processes for prepararing them
AT321295B (de) * 1971-11-11 1975-03-25 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen Thiazolo[5,4-d]-pyrimidin-Derivaten und ihren Salzen
CH653021A5 (fr) * 1981-04-24 1985-12-13 Delalande Sa Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant.
JPS60260579A (ja) * 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd ใƒ—ใƒชใƒณ่ช˜ๅฐŽไฝ“
GB8613591D0 (en) * 1986-06-04 1986-07-09 Roussel Lab Ltd Chemical compounds
DE3775527D1 (de) * 1986-10-22 1992-02-06 Ciba Geigy Ag 1,5-diphenylpyrazol-3-carbonsaeurederivate zum schuetzen von kulturpflanzen.
AU611437B2 (en) 1987-05-29 1991-06-13 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same
US5057517A (en) * 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5256398A (en) * 1990-11-08 1993-10-26 Whitby Research, Inc. Composition for determining viability of tissue
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dรฉrivรฉs du 3-pyrazolecarboxamide, procรฉdรฉ pour leur prรฉparation et compositions pharmaceutiques les contenant.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
CN1066448C (zh) * 1996-06-06 2001-05-30 ๆ ชๅผไผš็คพๅคงๅกšๅˆถ่ฏๅทฅๅœบ ้…ฐ่ƒบ่ก็”Ÿ็‰ฉ
EP0971588B1 (en) * 1997-01-21 2004-03-17 Smithkline Beecham Corporation Novel cannabinoid receptor modulators
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
US6579868B1 (en) * 1998-01-05 2003-06-17 Eisai Co., Ltd. Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes
JP3990061B2 (ja) * 1998-01-05 2007-10-10 ใ‚จใƒผใ‚ถใ‚คใƒปใ‚ขใƒผใƒซใƒปใ‚ขใƒณใƒ‰ใƒปใƒ‡ใ‚ฃใƒผใƒปใƒžใƒใ‚ธใƒกใƒณใƒˆๆ ชๅผไผš็คพ ใƒ—ใƒชใƒณ่ช˜ๅฐŽไฝ“ใŠใ‚ˆใณ็ณ–ๅฐฟ็—…ใฎไบˆ้˜ฒใƒปๆฒป็™‚ๅ‰คใจใ—ใฆใฎใ‚ขใƒ‡ใƒŽใ‚ทใƒณ๏ฝ๏ผ’ๅ—ๅฎนไฝ“ๆ‹ฎๆŠ—ๅ‰ค
IL141769A0 (en) * 1998-09-11 2002-03-10 Aventis Pharma Sa Azetidine derivatives, preparation and medicines containing them
FR2783246B1 (fr) 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
PT1221444E (pt) 1999-07-02 2005-11-30 Eisai Co Ltd Derivados de imidazole condensados e medicamentos para a diabetes mellitus
FR2799124B1 (fr) 1999-10-01 2004-08-13 Sanofi Synthelabo Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
MXPA02005100A (es) 1999-10-18 2003-09-25 Alexipharma Inc Derivados de pirazol antagonistas de receptor de canabinoide.
EP1223929B1 (en) 1999-10-18 2006-08-23 The University Of Connecticut Cannabimimetic indole derivatives
FR2800372B1 (fr) 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
FR2800375B1 (fr) 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
JP2004502642A (ja) * 2000-02-11 2004-01-29 ใƒ–ใƒชใ‚นใƒˆใƒซโˆ’ใƒžใ‚คใƒคใƒผใ‚บใ€€ใ‚นใ‚ฏใ‚คใƒ–ใ€€ใ‚ซใƒณใƒ‘ใƒ‹ใƒผ ใ‚ซใƒณใƒŠใƒ“ใƒŽใ‚คใƒ‰ใƒฌใ‚ปใƒ—ใ‚ฟใƒผใƒขใ‚ธใƒฅใƒฌใƒผใ‚ฟใƒผใ€ใใ‚Œใ‚‰ใฎ่ฃฝ้€ ๆ–นๆณ•ใ€ใŠใ‚ˆใณๅ‘ผๅธ็ณปใŠใ‚ˆใณ้žๅ‘ผๅธ็ณป็–พๆ‚ฃใฎๅ‡ฆ็ฝฎใฎใŸใ‚ใฎใ‚ซใƒณใƒŠใƒ“ใƒŽใ‚คใƒ‰ใƒฌใ‚ปใƒ—ใ‚ฟใƒผใƒขใ‚ธใƒฅใƒฌใƒผใ‚ฟใƒผใฎไฝฟ็”จ
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
CN1205188C (zh) * 2000-03-23 2005-06-08 ็ดขๅฐ”็“ฆ่ฏ็‰ฉๆœ‰้™ๅ…ฌๅธ ๅ…ทๆœ‰cb1๏ผๆ‹ฎๆŠ—ๆดปๆ€ง็š„4,5๏ผไบŒๆฐข๏ผ1h๏ผๅกๅ”‘่ก็”Ÿ็‰ฉ
FR2809621B1 (fr) 2000-05-12 2002-09-06 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
US20020091114A1 (en) * 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
CA2432148C (en) 2000-12-28 2011-01-18 Ono Pharmaceutical Co., Ltd. Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient
AU2002256690B2 (en) 2001-03-22 2006-05-18 Solvay Pharmaceuticals B.V. 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
ITMI20011483A1 (it) 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
WO2003007887A2 (en) 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
FR2829027A1 (fr) 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
JP2005507875A (ja) 2001-08-31 2005-03-24 ใƒฆใƒ‹ใƒใƒผใ‚ทใƒ†ใ‚ฃ ใ‚ชใƒ– ใ‚ณใƒใƒใ‚ซใƒƒใƒˆ ใ‚ซใƒณใƒŠใƒ“ใƒŽใ‚คใƒ‰ๅ—ๅฎนไฝ“ใซไฝœ็”จใ™ใ‚‹ๆ–ฐ่ฆใชใƒ”ใƒฉใ‚พใƒผใƒซ้กžไผผไฝ“
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
HUP0401567A3 (en) 2001-09-21 2005-06-28 Solvay Pharm Bv Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
US6974810B2 (en) 2001-09-21 2005-12-13 Solvay Pharmaceuticals B.V. 4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
US6509367B1 (en) * 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
JP2005532982A (ja) 2001-09-24 2005-11-04 ใƒใ‚คใ‚จใƒซใƒปใƒ•ใ‚ขใƒผใƒžใ‚ทใƒฆใƒผใƒใ‚ซใƒซใ‚บใƒปใ‚ณใƒผใƒใƒฌใƒผใ‚ทใƒจใƒณ ่‚ฅๆบ€ใฎๅ‡ฆ็ฝฎใฎใŸใ‚ใฎใƒ”ใƒญใƒผใƒซ่ช˜ๅฐŽไฝ“ใฎ่ฃฝ้€ ๅŠใณไฝฟ็”จ
HN2002000266A (es) 2001-09-24 2003-11-16 Bayer Corp Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
WO2003027114A1 (en) 2001-09-24 2003-04-03 Bayer Pharmaceuticals Corporation Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
SE0104332D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104330D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
US20050171161A1 (en) 2002-03-06 2005-08-04 Fong Tung M. Method of treatment or prevention of obesity
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
AR038966A1 (es) 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
WO2003082190A2 (en) 2002-03-26 2003-10-09 Merck & Co., Inc. Spirocyclic amides as cannabinoid receptor modulators
ES2192494B1 (es) 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
FR2837706A1 (fr) 2002-03-28 2003-10-03 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
AU2003225964B2 (en) 2002-03-28 2008-11-20 Merck Sharp & Dohme Corp. Substituted 2,3-diphenyl pyridines
CA2480856A1 (en) 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
FR2838439B1 (fr) 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
JP4459629B2 (ja) 2002-04-12 2010-04-28 ใƒกใƒซใ‚ฏ ใ‚จใƒณใƒ‰ ใ‚ซใƒ ใƒ‘ใƒ‹ใƒผ ใ‚คใƒณใ‚ณใƒผใƒใƒฌใƒผใƒ†ใƒƒใƒ‰ ไบŒ็’ฐๅผใ‚ขใƒŸใƒ‰
US6825209B2 (en) * 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
ES2287476T3 (es) 2002-05-10 2007-12-16 Smithkline Beecham Corporation Pirazolopirimidinas sustituidas.
EP1556373A1 (en) 2002-10-18 2005-07-27 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
JP2008517898A (ja) * 2004-10-22 2008-05-29 ใƒ•ใ‚กใ‚คใ‚ถใƒผใƒปใƒ—ใƒญใƒ€ใ‚ฏใƒ„ใƒปใ‚คใƒณใ‚ฏ ใƒ—ใƒชใƒณๅŒ–ๅˆ็‰ฉใ‚’่ชฟ่ฃฝใ™ใ‚‹ใŸใ‚ใฎๆ–นๆณ•

Also Published As

Publication number Publication date
EP1558615A1 (en) 2005-08-03
EG24662A (en) 2010-04-07
NO332195B1 (no) 2012-07-23
CN1955182A (zh) 2007-05-02
CY1107505T1 (el) 2013-03-13
AU2003269368B2 (en) 2008-10-30
TW200424202A (en) 2004-11-16
IS2602B (is) 2010-04-15
PT1558615E (pt) 2007-11-08
CO5560546A2 (es) 2005-09-30
EP1558615B8 (en) 2007-10-10
GEP20084325B (en) 2008-03-25
CA2503900A1 (en) 2004-05-06
JP3954618B2 (ja) 2007-08-08
AP1916A (en) 2008-11-10
AU2003269368A1 (en) 2004-05-13
TNSN05121A1 (fr) 2007-05-14
CN100439369C (zh) 2008-12-03
HRP20050378A2 (en) 2005-12-31
DE60316012D1 (de) 2007-10-11
JP2006505581A (ja) 2006-02-16
JP2007099779A (ja) 2007-04-19
GT200300232A (es) 2004-06-23
EA008176B1 (ru) 2007-04-27
UY28044A1 (es) 2004-05-31
CU23535A3 (es) 2010-06-17
CN100478343C (zh) 2009-04-15
ECSP055767A (es) 2005-08-11
ATE371658T1 (de) 2007-09-15
MY140010A (en) 2009-11-30
CA2503900C (en) 2009-06-02
KR100674560B1 (ko) 2007-02-28
DE60316012T2 (de) 2008-05-29
ZA200503378B (en) 2006-07-26
PE20040781A1 (es) 2004-11-20
TWI327567B (en) 2010-07-21
NO20052512L (no) 2005-05-25
MA27479A1 (fr) 2005-08-01
DOP2003000742A (es) 2004-04-30
NO20052512D0 (no) 2005-05-25
RS20050395A (sr) 2007-04-10
NZ539589A (en) 2007-10-26
US20060241120A1 (en) 2006-10-26
BR0314918A (pt) 2005-08-02
OA13080A (en) 2006-11-10
SG148071A1 (en) 2008-12-31
WO2004037823A1 (en) 2004-05-06
RS20050306A (sr) 2007-04-10
KR20050070093A (ko) 2005-07-05
NL1024643A1 (nl) 2004-05-03
AP2005003290A0 (en) 2005-06-30
US20040092520A1 (en) 2004-05-13
CR7812A (es) 2005-06-08
HK1081189A1 (zh) 2006-05-12
EA200500520A1 (ru) 2005-12-29
CN1955181A (zh) 2007-05-02
HK1099762A1 (zh) 2007-08-24
MXPA05003882A (es) 2005-06-22
PL376311A1 (en) 2005-12-27
DK1558615T3 (da) 2007-12-03
US7129239B2 (en) 2006-10-31
NL1024643C2 (nl) 2005-02-01
IS7801A (is) 2005-04-14
ES2291669T3 (es) 2008-03-01
UA79507C2 (en) 2007-06-25
CN1708499A (zh) 2005-12-14
EP1558615B1 (en) 2007-08-29

Similar Documents

Publication Publication Date Title
AR041835A1 (es) Compuestos de purina y usos de los mismos
AR044539A1 (es) Ligandos de receptores de canabinoides y sus usos
AR043038A1 (es) Compuestos de pirazolotriazina y usos de los mismos
ES2515095T3 (es) Derivados de adamantil acetamida como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1
ES2515194T3 (es) Derivados de pirrolidina
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
ES2594409T3 (es) Derivados de heteroarilo como moduladores del nAChR รก7
AR048669A1 (es) Derivados biciclicos de bisamida
PE20090820A1 (es) Derivados de piperidina/piperazina
CO5640111A2 (es) Ligandos del receptor cannabinoide y usos de los mismos
AR049647A1 (es) Cis-imidazolinas
AR064459A1 (es) Derivados de sulfonamida
AR076900A1 (es) Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc
ES2382715T3 (es) Derivados de pirazol[3,4-B]piridina como inhibidores de fosfodiesterasa
NO20075768L (no) Hydroksybenzamidderivater og deres anvendelse som inhibitorer av HSP90
CO6241121A2 (es) Derivados de azapeptidps
AR083953A1 (es) Compuestos para tratar enfermedades neurodegenerativas
CO5680399A2 (es) Inhibidores de fosfodiesterasa 4, que incluyen analogos de anilina y difenilamina n-sustituidos
AR047678A1 (es) Derivados de benzamidas y su uso como activadores de glucoquinasa
AR070193A1 (es) Terapia combinada que comprende inhibidores de sglt e inhibidores de dpp4, composicion farmaceutica y uso
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR044795A1 (es) Derivados de pirido [2,1-a] isoquinolina como inhibidores de la dpp-iv
AR051202A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad

Legal Events

Date Code Title Description
FG Grant, registration